Abstract
This cross-sectional study examines utilization trends for filgrastim and infliximab products and their biosimilars to understand whether biosimilars are associated with reduced spending in Medicare Part D.
| Original language | English (US) |
|---|---|
| Pages (from-to) | e221117 |
| Journal | JAMA Network Open |
| Volume | 5 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 7 2022 |
Keywords
- Aged
- Biosimilar Pharmaceuticals/therapeutic use
- Filgrastim/therapeutic use
- Humans
- Infliximab/therapeutic use
- Medicare Part D
- United States
PubMed: MeSH publication types
- Letter
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
Fingerprint
Dive into the research topics of 'Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS